Johan Malm

1.2k total citations
25 papers, 995 citations indexed

About

Johan Malm is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Molecular Biology. According to data from OpenAlex, Johan Malm has authored 25 papers receiving a total of 995 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Johan Malm's work include Thyroid Disorders and Treatments (17 papers), Estrogen and related hormone effects (9 papers) and Growth Hormone and Insulin-like Growth Factors (7 papers). Johan Malm is often cited by papers focused on Thyroid Disorders and Treatments (17 papers), Estrogen and related hormone effects (9 papers) and Growth Hormone and Insulin-like Growth Factors (7 papers). Johan Malm collaborates with scholars based in United States, Sweden and France. Johan Malm's co-authors include Gary J. Grover, Karin Mellström, John D. Baxter, Yilin Li, Bo Carlsson, Neeraj Garg, Charlotta Mellin, Stefan Rehnmark, Lars-Göran Bladh and Paul G. Sleph and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and The FASEB Journal.

In The Last Decade

Johan Malm

25 papers receiving 920 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johan Malm United States 16 545 313 262 129 118 25 995
Ralph Mosley United States 12 163 0.3× 698 2.2× 65 0.2× 172 1.3× 218 1.8× 15 1.2k
Monica Einstein United States 10 410 0.8× 432 1.4× 257 1.0× 88 0.7× 45 0.4× 14 826
Paige E. Mahaney United States 15 203 0.4× 487 1.6× 111 0.4× 320 2.5× 66 0.6× 27 1.0k
George J. Eiermann United States 22 660 1.2× 561 1.8× 46 0.2× 215 1.7× 95 0.8× 30 1.4k
R. Kirk McPherson United States 18 272 0.5× 815 2.6× 52 0.2× 340 2.6× 227 1.9× 25 1.2k
Dana S. Kuruvilla United States 12 87 0.2× 748 2.4× 81 0.3× 59 0.5× 225 1.9× 13 1.0k
Rafał R. Siciński United States 17 100 0.2× 282 0.9× 375 1.4× 297 2.3× 39 0.3× 84 1.3k
Michael L. Mohler United States 19 416 0.8× 419 1.3× 269 1.0× 218 1.7× 67 0.6× 31 1.1k
David E. Magee United States 13 340 0.6× 359 1.1× 877 3.3× 162 1.3× 56 0.5× 17 1.3k
Fuyong Du United States 11 258 0.5× 238 0.8× 37 0.1× 147 1.1× 54 0.5× 17 548

Countries citing papers authored by Johan Malm

Since Specialization
Citations

This map shows the geographic impact of Johan Malm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Malm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Malm more than expected).

Fields of papers citing papers by Johan Malm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Malm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Malm. The network helps show where Johan Malm may publish in the future.

Co-authorship network of co-authors of Johan Malm

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Malm. A scholar is included among the top collaborators of Johan Malm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Malm. Johan Malm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rehnmark, Stefan, Padideh Davoodpour, Giuseppe Danilo Norata, et al.. (2013). The Thyroid Receptor Modulator KB3495 Reduces Atherosclerosis Independently of Total Cholesterol in the Circulation in ApoE Deficient Mice. PLoS ONE. 8(12). e78534–e78534. 7 indexed citations
2.
Malm, Johan, Mathias Färnegårdh, Gary J. Grover, & Paul W. Ladenson. (2009). Thyroid Hormone Antagonists: Potential Medical Applications and Structure Activity Relationships. Current Medicinal Chemistry. 16(25). 3258–3266. 18 indexed citations
3.
Grover, Gary J. & Johan Malm. (2008). Pharmacological Profile of the Selective Mitochondrial F1F0ATP Hydrolase Inhibitor BMS‐199264 in Myocardial Ischemia. Cardiovascular Therapeutics. 26(4). 287–296. 26 indexed citations
4.
Khan, Akhtar, Stefan Rehnmark, Jamie Boulet, et al.. (2008). Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor β subtype selective agonist KB-141. The Journal of Steroid Biochemistry and Molecular Biology. 111(3-5). 262–267. 82 indexed citations
5.
Malm, Johan, et al.. (2007). Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorganic & Medicinal Chemistry Letters. 17(7). 2018–2021. 8 indexed citations
6.
Grover, Gary J., Karin Mellström, & Johan Malm. (2007). Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes. Current Vascular Pharmacology. 5(2). 141–154. 32 indexed citations
7.
Grover, Gary J., et al.. (2007). Anti‐Obesity, Lipid‐lowering, and Anti‐Diabetic Effects of The Selective Thyroid Receptor Beta Agonist KB‐141. The FASEB Journal. 21(5). 1 indexed citations
8.
Berkenstam, Anders, Jens D. Kristensen, Karin Mellström, et al.. (2007). The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proceedings of the National Academy of Sciences. 105(2). 663–667. 155 indexed citations
9.
Grover, Gary J., Karin Mellström, & Johan Malm. (2006). Development of the Thyroid Hormone Receptor β-Subtype Agonist KB-141 : A Strategy for Body Weight Reduction and Lipid Lowering with Minimal Cardiac Side Effects. Cardiovascular Drug Reviews. 23(2). 133–148. 50 indexed citations
10.
Malm, Johan, G. J. Grover, & Mathias Färnegårdh. (2006). Recent Advances in the Development of Agonists Selective for β1-Type Thyroid Hormone Receptor. Mini-Reviews in Medicinal Chemistry. 7(1). 79–86. 18 indexed citations
11.
Koehler, Konrad F., Sandra Gordon, Peter Brandt, et al.. (2006). Thyroid Receptor Ligands. 6. A High Affinity “Direct Antagonist” Selective for the Thyroid Hormone Receptor. Journal of Medicinal Chemistry. 49(23). 6635–6637. 29 indexed citations
12.
Li, Yilin, Konrad F. Koehler, Karin Mellström, et al.. (2005). Thyroid receptor ligands. Part 4: 4′-amido bioisosteric ligands selective for the thyroid hormone receptor beta. Bioorganic & Medicinal Chemistry Letters. 16(4). 884–886. 20 indexed citations
13.
Koehler, Konrad F., Neeraj Garg, Mathias Färnegårdh, et al.. (2005). Thyroid receptor ligands. Part 5: Novel bicyclic agonist ligands selective for the thyroid hormone receptor β. Bioorganic & Medicinal Chemistry Letters. 16(5). 1240–1244. 20 indexed citations
14.
Carlsson, Bo, Lars-Göran Bladh, Peter Agback, et al.. (2005). Thyroid Receptor Ligands. 3. Design and Synthesis of 3,5-Dihalo-4-alkoxyphenylalkanoic Acids as Indirect Antagonists of the Thyroid Hormone Receptor. Journal of Medicinal Chemistry. 48(9). 3114–3117. 20 indexed citations
15.
Hangeland, Jon J., Arthur M. Doweyko, Tamara Dejneka, et al.. (2004). Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorganic & Medicinal Chemistry Letters. 14(13). 3549–3553. 47 indexed citations
16.
Malm, Johan. (2004). Thyroid Hormone Ligands and Metabolic Diseases. Current Pharmaceutical Design. 10(28). 3525–3532. 22 indexed citations
17.
Malm, Johan. (2004). Therapeutic thyroid hormone ligand patents 1998 – 2003. Expert Opinion on Therapeutic Patents. 14(8). 1169–1183. 4 indexed citations
18.
Grover, Gary J., Karin Mellström, Ye Liu, et al.. (2003). Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proceedings of the National Academy of Sciences. 100(17). 10067–10072. 181 indexed citations
19.
Liu, Ye, Yilin Li, Karin Mellström, et al.. (2003). Thyroid Receptor Ligands. 1. Agonist Ligands Selective for the Thyroid Receptor β1. Journal of Medicinal Chemistry. 46(9). 1580–1588. 120 indexed citations
20.
Carlsson, Bo, Bramah N. Singh, Stefan Nilsson, et al.. (2002). Synthesis and Preliminary Characterization of a Novel Antiarrhythmic Compound (KB130015) with an Improved Toxicity Profile Compared with Amiodarone. Journal of Medicinal Chemistry. 45(3). 623–630. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ralph Mosley Breakdown of academic impact, for papers by Monica Einstein Breakdown of academic impact, for papers by Paige E. Mahaney Breakdown of academic impact, for papers by George J. Eiermann Breakdown of academic impact, for papers by R. Kirk McPherson Breakdown of academic impact, for papers by Dana S. Kuruvilla Breakdown of academic impact, for papers by Rafał R. Siciński Breakdown of academic impact, for papers by Michael L. Mohler Breakdown of academic impact, for papers by David E. Magee Breakdown of academic impact, for papers by Fuyong Du
Rankless by CCL
2026